Cite
HARVARD Citation
Morabito, F. et al. (2021). Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials. American journal of hematology. 96 (8), pp. E269-E272. [Online].